351410-47-4 Usage
General Description
(5-Bromo-2-methoxypyridin-3-yl)methanol is a chemical compound with the molecular formula C7H8BrNO2. It is a pyridine derivative, containing a bromine atom, a methoxy group, and a hydroxymethyl group attached to the pyridine ring. (5-Bromo-2-methoxypyridin-3-yl)methanol is commonly used as an intermediate in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It has potential applications in the development of new drugs and agricultural products due to its structural versatility and reactivity. Additionally, the presence of the bromine atom makes it useful in the synthesis of other organic compounds. Overall, (5-Bromo-2-methoxypyridin-3-yl)methanol plays a significant role in the field of organic chemistry and pharmaceutical research.
Check Digit Verification of cas no
The CAS Registry Mumber 351410-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,4,1 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 351410-47:
(8*3)+(7*5)+(6*1)+(5*4)+(4*1)+(3*0)+(2*4)+(1*7)=104
104 % 10 = 4
So 351410-47-4 is a valid CAS Registry Number.
351410-47-4Relevant articles and documents
NEW MACROCYCLIC LRRK2 KINASE INHIBITORS
-
, (2021/11/13)
Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.
Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof
-
Paragraph 0399; 0408-0410, (2020/05/02)
The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,
Substituted Pyrrolidines and Methods of Use
-
Paragraph 1527, (2018/04/20)
The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
